Signs and Symptoms of Adrenal Medullary Hyperplasia vs Pheochromocytoma
Patients with AMH without pheochromocytoma had milder symptoms compared with patients with pheochromocytoma only.
Cushing Syndrome
Mifepristone an Effective Alternative to Surgery for Patients With Bilateral Macronodular Adrenal Hyperplasia
Mifepristone may be an effective alternative to adrenalectomy in patients with hypercortisolism caused by primary bilateral macronodular adrenal hyperplasia.
Transsphenoidal Surgery Recommended for Cushing Disease With Inconclusive or Normal MRI
In the absence of clear evidence of a pituitary adenoma on imaging, there is some controversy regarding the best treatment for Cushing disease.
High Prevalence of Diabetes in Patients With Primary Aldosteronism
Prevalence of diabetes is higher in patients with primary aldosteronism and was found to be related to suspected subclinical hypercortisolism.
Levoketoconazole Improves Biochemical and Clinical Parameters in Patients With Cushing Syndrome
Biochemical markers and clinical signs and symptoms of endogenous Cushing syndrome improved after 6 months of levoketoconazole therapy.
New Data for Potential Cushing Syndrome Treatment Levoketoconazole Announced
Researchers reported that mean urinary-free cortisol (mUFC) normalization with Recorlev was similar in patients with and without diabetes.
Cushing Syndrome in Pregnancy: When to Suspect and How to Treat
Despite the preponderance of CS in women of childbearing age and the likelihood of pregnancy triggering CS, the condition is often overlooked because of the overlap of pregnancy and hypercortisolism symptoms.
Elevated Plasma Agouti-Related Protein May Be a Marker for Cushing Disease
Plasma levels of the orexigenic neuropeptide agouti-related protein (AgRP) are elevated in Cushing disease, and it may be a marker of hypothalamic AgRP.
Cushing Syndrome Results in Poor Quality of Life Even After Remission
Although patients reach clinical and biochemical remission, patients exposed to hypercortisolism do not show functional remission.
Positive Results for Recorlev in Phase 3 Cushing Syndrome Trial
Results from this single-arm, open-label study found that 30% of patients achieved normalization of mean urinary free cortisol (UFC) after 6 months of maintenance treatment with levoketoconazole, without a dose increase (P<.25).
Next post in Adrenal
